Julien Dimastromatteo

WORK HISTORY

EDUCATION

SKILLS

ABOUT JULIEN DIMASTROMATTEO

I am an executive leader in drug development focused on translating rigorous science into investable therapeutic programs.I lead translational and clinical strategy as part of the executive team at Dominion Cannabinoids, and clinical development planning for an intranasal brain-delivery platform targeting neuropsychiatric conditions where current systemic therapies are limited by blood–brain barrier constraints and dose-limiting side effects. Our approach is built around a clear thesis: precision brain delivery, guided by pharmacokinetic and mechanistic insight, can materially improve therapeutic impact while reducing early-stage development risk.My work centers on de-risking innovation. That means designing PK/PD-informed programs, aligning preclinical models with clinical endpoints, preparing regulatory strategy early, and structuring development pathways that are both scientifically defensible and capital efficient. I operate at the intersection of translational science, clinical planning, and strategic execution.My background includes molecular imaging, pharmacology, and first-in-human research. I have contributed to first-in-human research and clinical-stage development strategy across CNS and imaging programs. I currently serve as Section Editor for *Molecular Imaging & Biology*, evaluating emerging technologies that bridge discovery and clinical application. Across roles, I focus on one objective: turning complex biological hypotheses into structured, testable, and value-creating development plans.I am particularly interested in:• CNS therapeutics with mechanistic clarity• Brain-targeted delivery technologies• Early clinical strategy and regulatory positioning• Partnerships that accelerate translational progressBiotech value is created when scientific depth meets disciplined strategy. My role is to ensure that innovation is not only novel—but executable, scalable, and investable.We are building a capital-efficient CNS development platform designed to generate decisive clinical insight early. I welcome conversations with investors and partners who value disciplined science and strategic execution.